P03277

DRUG4 trials

Sponsors

Guerbet

Conditions

Blood Brain Barrier DefectBody IndicationBrain LesionCNS LesionCentral Nervous System IndicationHealthy VolunteersPediatric PatientsRenal Insufficiency

Phase 1

Pharmacokinetics, Pharmacodynamics Profile and Tolerance of P03277 in Healthy Subjects and Patients With Brain Lesions

CompletedNCT03603106

GuerbetBrain Lesion, Healthy Volunteers

Start: 2013-11-25End: 2015-04-17Updated: 2021-05-14

Pharmacokinetics, Dialysability and Safety of P03277 in Healthy Volunteers and in Patients With Impaired Renal Function

CompletedNCT03657784

GuerbetHealthy Volunteers, Renal Insufficiency

Start: 2017-10-13End: 2019-08-23Updated: 2019-10-22

Phase 2

P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

CompletedNCT02633501

GuerbetBlood Brain Barrier Defect, CNS Lesion

Start: 2016-06-30End: 2018-01-31Updated: 2021-10-25

Pharmacokinetics, Safety and Efficacy of P03277 in Pediatric Patients Undergoing Central Nervous System Contrast-enhanced MRI

CompletedNCT03749252

GuerbetBody Indication, Central Nervous System Indication, Pediatric Patients

Start: 2018-11-06End: 2020-08-10Updated: 2022-06-01

Related Papers

Assessment of Pharmacokinetic, Pharmacodynamic Profile, and Tolerance of Gadopiclenol, A New High Relaxivity GBCA, in Healthy Subjects and Patients With Brain Lesions (Phase I/IIa Study)

Investigative Radiology2019-03-1351 citations